Reversal of arterial disease by modulating magnesium and phosphate (roadmap-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease

HIGHLIGHTS

SUMMARY

Background and rationale {6a} Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). Multiple in_vitro and animal studies demonstrate that magnesium can effectively prevent mineralization in experimental models of vascular calcification and improve calcification propensity. Currently, most magnesium intervention studies with focus on calcification propensity or arterial stiffness have been performed in a relatively healthy population or patients with ESRD. The aim of this study is to assess the effect on arterial stiffness of the combined use of magnesium supplementation and phosphate binder therapy during 24 weeks . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.